Abstract |
The aim of this study was to investigate the relations between the plasma concentrations of spiraprilat (the active metabolite of the angiotensin-converting enzyme inhibitor spirapril) and its effects on plasma converting enzyme activity (PCEA), pulmonary capillary wedge pressure (PCWP), and brachial blood flow (BBF), after a single oral administration of 6 mg of spirapril in eight patients with severe congestive heart failure (CHF). Concentrations and effects were determined before and repeatedly during 48 h after drug intake. A sigmoid model was fitted to individual observations. Maximal effects, concentrations inducing half-maximal effects, and Hill coefficients were -99 +/- 2%, 3.9 +/- 1.9 ng/ml, and 2.4 +/- 0.7 for PCEA inhibition, -15 +/- 8 mm Hg, 11.8 +/- 9.2 ng/ml, and 2.6 +/- 1.3 for PCWP decrease, and 36 +/- 19 ml/min, 13.8 +/- 7.6 ng/ml, and 3.3 +/- 1.0 for BBF increase. In severe CHF, although a 14 ng/ml plasma concentration of spiraprilat may induce a 95% inhibition of PCEA, a 30 ng/ml plasma concentration is mandatory to normalize PCWP and BBF. This concentration corresponds to the peak achieved after a 6-mg oral dose of spirapril.
|
Authors | E Bellissant, N P Chau, C Thuillez, C Gerbeau, C Richard, J F Giudicelli |
Journal | Journal of cardiovascular pharmacology
(J Cardiovasc Pharmacol)
Vol. 30
Issue 2
Pg. 253-60
(Aug 1997)
ISSN: 0160-2446 [Print] United States |
PMID | 9269955
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Enalapril
- Peptidyl-Dipeptidase A
- spiraprilat
|
Topics |
- Angiotensin-Converting Enzyme Inhibitors
(blood, pharmacokinetics, pharmacology)
- Enalapril
(analogs & derivatives, blood, pharmacokinetics, pharmacology)
- Heart Failure
(drug therapy, physiopathology)
- Hemodynamics
(drug effects)
- Humans
- Middle Aged
- Models, Biological
- Peptidyl-Dipeptidase A
(blood)
- Pulmonary Circulation
(drug effects)
- Pulmonary Wedge Pressure
(drug effects)
- Regional Blood Flow
(drug effects)
- Vascular Resistance
(drug effects)
|